Novartis announces results from updated analysis of Phase 3 trial of Kisqali

Novartis (NVS) announced results from an updated analysis of the pivotal Phase 3 NATALEE trial of Kisqali that it says “underscore the extended efficacy beyond the duration of treatment in combination with endocrine therapy.” Results showed a sustained reduction in distant recurrence of 28.5% , compared to ET alone, in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer. These late-breaking data are being presented at the 2024 San Antonio Breast Cancer Symposium. “In day-to-day practice, we see a real and persistent risk of breast cancer coming back after early diagnosis, often as metastatic disease,” said Paolo Tarantino, M.D., Advanced Fellow at Dana-Farber Cancer Institute and Harvard Medical School. “The latest NATALEE and real-world data presented at SABCS reaffirm we can better address risk of recurrence for all patients at high-risk, including selected patients with node-negative disease, by offering them adjuvant CDK4/6 inhibitor treatment in addition to endocrine therapy.”